25.04.2017

MagForce AG to host Symposium for Focal Therapy in Glioblastoma at WFNOS 2017 Meeting

Berlin, Germany, and Nevada, USA, April 25, 2017 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a Scientific Symposium titled “Focal Therapy in Glioblastoma ...

 

12.04.2017

MagForce AG participates in six upcoming international conferences in Q2 2017

Berlin, Germany and Nevada, USA, April 12, 2017 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in six upcoming scientific and investor conferences in the second ...

 

02.03.2017

MagForce AG Publishes its First Shareholder Letter 2017

Berlin, Germany, and Nevada, USA, March 02, 2017 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published its first Shareholder Letter 2017:

 

23.01.2017

MagForce AG presents NanoTherm™ therapy for the treatment of brain tumors at ECCO2017 from January 27-30, 2017 in Amsterdam

Berlin, Germany and Nevada, USA, January 23rd, 2017 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today its attendance at ECCO2017, the European Cancer Congress held by the ...

 

02.12.2016

MagForce AG supports NOA Winter School 2016 from December 01-02 in Münster, Germany

Berlin, Germany and Nevada, USA, December 02, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Company supports NOA Winter School 2016 held by the ...